Anti-Müllerian hormone in African-American women with systemic lupus erythematosus. Issue 1 (1st November 2020)

• Record Type: Journal Article
• Authors: Angley, Meghan; Spencer, Jessica B; Lim, S Sam; Howards, Penelope P
• Is Part Of: Lupus science & medicine. Volume 7:Issue 1(2020)
• Publication Date: 2020-11-01
• Subjects: lupus erythematosus -- systemic -- cyclophosphamide -- inflammation; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2020-000439
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Objective: Women with SLE may experience ovarian insufficiency or dysfunction due to treatment or disease effects. Anti-Müllerian hormone (AMH), a marker of ovarian reserve, has been examined in small populations of women with SLE with conflicting results. To date, these studies have included very few African-American women, the racial/ethnic group at greatest risk of SLE. Methods: We enrolled African-American women aged 22–40 years diagnosed with SLE after age 17 from the Atlanta Metropolitan area. Women without SLE from the same area were recruited from a marketing list for comparison. AMH was measured in serum using the Ansh Labs assay (Webster, Texas, USA). We considered AMH levels <1.0 ng/mL and AMH <25th percentile of comparison women as separate dichotomous outcomes. Log-binomial regression models estimating prevalence ratios were adjusted for age, body mass index and hormonal contraception use in the previous year. Results: Our sample included 83 comparison women without SLE, 68 women with SLE and no history of cyclophosphamide (SLE/CYC−) and 11 women with SLE and a history of cyclophosphamide treatment (SLE/CYC+). SLE/CYC+ women had a greater prevalence of AMH <1.0 ng/mL compared with women without SLE (prevalence ratio (PR): 2.90, 95% CI: 1.29 to 6.51). SLE/CYC− women were also slightly more likely to have AMH <1.0 ng/mL (PR: 1.62, 95% CI: 0.93 to 2.82) than comparison women. Results were similar when considering AMH <25th percentile by age of comparison women. Conclusions: Treatment with CYC is associated with low AMH in African-American women with SLE. SLE itself may also be associated with reduced AMH, but to a lesser extent.